Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.38 |
| ▸ | SKP1 | P63208 | 1/20 | 0.38 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30937057 | 1.00 | PIM1 (0.44) | PIM1PIM3PIM2DDB1CRBN | |
| SCHEMBL31715927 | 1.00 | PIM1 (0.44) | PIM1PIM3PIM2DDB1CRBN | |
| SCHEMBL30408483 | 0.93 | CRBN (0.43) | PIM1PIM3PIM2DDB1CRBN | |
| SCHEMBL30937045 | 0.88 | CRBN (0.40) | PIM1PIM3PIM2DDB1CRBN | |
| SCHEMBL31715966 | 0.85 | CRBN (0.38) | PIM3DDB1CRBN | |
| SCHEMBL31155517 | 0.84 | CRBN (0.43) | DDB1CRBN | |
| SCHEMBL31155500 | 0.84 | CRBN (0.43) | DDB1CRBN | |
| SCHEMBL30937153 | 0.83 | DDB1 (0.43) | PIM1PIM3PIM2DDB1CRBN | |
| SCHEMBL30937032 | 0.82 | DDB1 (0.43) | PIM1PIM3PIM2DDB1CRBN | |
| SCHEMBL30937180 | 0.81 | CRBN (0.41) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| EP-4608816-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | Monte Rosa Therapeutics AG (CH) | 2025-09-03 | — | — | EP | disclosed |
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-21 | — | — | US | disclosed |
| WO-2024092039-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263395-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | PIM1 1354/4885PIM3 1629/4885PIM2 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.